David Ricks, Eli Lilly CEO (Jeenah Moon/Bloomberg via Getty Images)
January 14, 2025 03:38 PM ESTUpdated January 15, 04:35 AM
Pharma
Manufacturing

Eli Lil­ly miss­es 2024 rev­enue ex­pec­ta­tions, stock dips 7%

Nicole DeFeudis

Editor

Eli Lil­ly ex­pects to miss its re­cent rev­enue es­ti­mate for 2024 by about $400 mil­lion, ac­cord­ing to a pre­lim­i­nary re­port.

The com­pa­ny’s es­ti­mates have var­ied …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times